European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia (y 2)

(3) Arnold, L, et al. A Double-Blind, Multicenter Trial Comparing Duloxetine with Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder. Arthritis Rheum 2004; 50(9):2974-84.

(4) Chappell, AS, et al. Duloxetine 60-120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome. Poster presented at the American College of Rheumatology Annual Meeting; Nov 2007, Boston, MA.

(5) Chappell, AS, et al. A 1-Year Safety and Efficacy Study of Duloxetine in Patients with Fibromyalgia. Poster presented at European League Against Rheumatism Annual Meeting; Jun 2008, Paris, France.

(6) Leventhal, LJ. Management of Fibromyalgia. Annals of Internal Medicine. 1999; 131: 850-858.

(7) Arnold, L, et al. Family Study of Fibromyalgia. Arthritis & Rheumatism. 2004; 50(3): 944-952.

(8) White, et al. Classification, Epidemiology, and Natural History of Fibromyalgia. Current Pain and Headache Reports 2001; 5:3320-329

(9) Epstein, SA, et al. Psychiatric Disorders in Patients with Fibromyalgia. Psychosomatics. 1999; 40(1):59

(10) Rao, SG, et al. Understanding the Fibromyalgia Syndrome. Psychopharmacology Bulletin. 2007: 4:24-67

(11) Carville, SF, et al. EULAR Evidence-based Recommendations for the Management of Fibromyalgia Syndrome. Ann Rheum Dis. Republished 2008: 67: 536-541.

P--LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20070319/NYM004LOGO )

Charlie McAtee, +1-317-277-1566, Sonja Popp-Stahly, +1-317-655-2993, both of Eli Lilly and Company; or John Pugh, Boehringer Ingelheim, +49-6132-77-2964; Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070319/NYM004LOGO, PRN Photo Desk, photodesk@prnewswire.com